93
25. Taheri S. The link between short sleep duration and obesity: we should recommend more sleep
to prevent obesity. Arch Dis Childhood. 2006;91(11):881–4.
26. Mahat B, Chassé É, Mauger J-F, Imbeault P. Effects of acute hypoxia on human adipose tissue
lipoprotein lipase activity and lipolysis. J Transl Med. 2016;14(1):212.
27. Paudel MS, Tiwari A, Mandal A, Shrestha B, Kafle P, Chaulagai B, et al. Metabolic syndrome
in patients with non-alcoholic fatty liver disease: a community based cross-sectional study.
Cureus. 2019;11(2):e4099.
28. Janardhan SV. Common misconceptions in hepatology: nonalcoholic fatty liver disease. Clin
Liver Dis. 2019;13(3):79.
29. Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(24):3009.
30. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–27.
31. Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease:
interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract.
2016;2016:2862173.
32. You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019;70(2):237–48.
33. Li B, Lei S-S, Su J, Cai X-M, Xu H, He X, et al. Alcohol induces more severe fatty liver
disease by influencing cholesterol metabolism. Evid-Based Complement Alternat Med.
2019;2019:7095684.
34. Wong VW-S, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and
for alcoholic hepatitis. Transl Gastroenterol Hepatol. 2019;4:53.
35. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver
disease. Metabolism. 2016;65(8):1183–95.
36. Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, et al. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab.
2019;29:99–113.
37. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying
molecular mechanisms. J Cell Physiol. 2019;234(6):8152–61.
38. Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L, et al. Role of
diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366:l2368.
39. Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: fire from within. Int
J Mol Sci. 2019;20(3):562.
40. Ekpenyong CE. Relationship between insulin resistance and metabolic syndrome clusters: current knowledge. Acta Sci Med Sci. 2019;3:99–104.
41. Yan Y-Z, Ma R-L, Zhang J-Y, He J, Ma J-L, Pang H-R, et al. Association of insulin resistance with glucose and lipid metabolism: ethnic heterogeneity in far Western China. Mediat
Inflamm. 2016;2016:3825037.
42. Li T, Chen K, Liu G, Huang L-P, Chen L, Wang Q-W, et al. Calorie restriction prevents the
development of insulin resistance and impaired lipid metabolism in gestational diabetes offspring. Pediatr Res. 2017;81(4):663.
43. J-a K, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res.
2008;102(4):401–14.
44. Sergi D, Naumovski NN, Heilbronn LHK, Abeywardena M, O'Callaghan N, Lionetti L, et al.
Mitochondrial (Dys) function and insulin resistance: from pathophysiological molecular
mechanisms to the impact of diet. Front Physiol. 2019;10:532.
45. Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang D, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc Natl
Acad Sci. 2014;111(26):9597–602.
46. Sokolowska E, Błachnio-Zabielska AU. The role of ceramides in insulin resistance. Front
Endocrinol. 2019;10:577.
5 Impaired Lipid Metabolism in Metabolic Disorders
25. Taheri S. The link between short sleep duration and obesity: we should recommend more sleep
to prevent obesity. Arch Dis Childhood. 2006;91(11):881–4.
26. Mahat B, Chassé É, Mauger J-F, Imbeault P. Effects of acute hypoxia on human adipose tissue
lipoprotein lipase activity and lipolysis. J Transl Med. 2016;14(1):212.
27. Paudel MS, Tiwari A, Mandal A, Shrestha B, Kafle P, Chaulagai B, et al. Metabolic syndrome
in patients with non-alcoholic fatty liver disease: a community based cross-sectional study.
Cureus. 2019;11(2):e4099.
28. Janardhan SV. Common misconceptions in hepatology: nonalcoholic fatty liver disease. Clin
Liver Dis. 2019;13(3):79.
29. Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(24):3009.
30. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–27.
31. Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease:
interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract.
2016;2016:2862173.
32. You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019;70(2):237–48.
33. Li B, Lei S-S, Su J, Cai X-M, Xu H, He X, et al. Alcohol induces more severe fatty liver
disease by influencing cholesterol metabolism. Evid-Based Complement Alternat Med.
2019;2019:7095684.
34. Wong VW-S, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and
for alcoholic hepatitis. Transl Gastroenterol Hepatol. 2019;4:53.
35. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver
disease. Metabolism. 2016;65(8):1183–95.
36. Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, et al. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab.
2019;29:99–113.
37. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying
molecular mechanisms. J Cell Physiol. 2019;234(6):8152–61.
38. Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L, et al. Role of
diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366:l2368.
39. Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: fire from within. Int
J Mol Sci. 2019;20(3):562.
40. Ekpenyong CE. Relationship between insulin resistance and metabolic syndrome clusters: current knowledge. Acta Sci Med Sci. 2019;3:99–104.
41. Yan Y-Z, Ma R-L, Zhang J-Y, He J, Ma J-L, Pang H-R, et al. Association of insulin resistance with glucose and lipid metabolism: ethnic heterogeneity in far Western China. Mediat
Inflamm. 2016;2016:3825037.
42. Li T, Chen K, Liu G, Huang L-P, Chen L, Wang Q-W, et al. Calorie restriction prevents the
development of insulin resistance and impaired lipid metabolism in gestational diabetes offspring. Pediatr Res. 2017;81(4):663.
43. J-a K, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res.
2008;102(4):401–14.
44. Sergi D, Naumovski NN, Heilbronn LHK, Abeywardena M, O'Callaghan N, Lionetti L, et al.
Mitochondrial (Dys) function and insulin resistance: from pathophysiological molecular
mechanisms to the impact of diet. Front Physiol. 2019;10:532.
45. Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang D, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc Natl
Acad Sci. 2014;111(26):9597–602.
46. Sokolowska E, Błachnio-Zabielska AU. The role of ceramides in insulin resistance. Front
Endocrinol. 2019;10:577.
5 Impaired Lipid Metabolism in Metabolic Disorders